A large body of evidence has indicated that PI3K/AKT pathway critically contributes to drug resistance in human cancer [31] and inactivation of PI3K/AKT by PP might lead to alternation of drug sensitivity in liver cancer cells. This evidence concerns the gene AKT1 and cancer.